Evaluation for NCI Surgery Branch Clinical Research Protocols
This study is trying to see if patients with cancer can join new treatment trials by checking their tumors for certain genetic changes and proteins.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 7000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT00001823 on ClinicalTrials.gov |
What this trial studies
This observational study involves screening and evaluating patients for participation in clinical research protocols at the National Cancer Institute Surgery Branch. Patients aged 18 and older with suspected or confirmed malignant diseases will undergo a series of tests, including laboratory tests and imaging, to determine their eligibility for experimental therapies. The study aims to assess the frequency of specific genetic mutations and neoantigens in tumors, which may inform future treatment protocols. The goal is to identify suitable candidates for innovative cancer therapies involving immune cell manipulation.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with suspected or biopsy-proven malignant diseases.
Not a fit: Patients who are pregnant or planning to become pregnant may not benefit due to the risks associated with certain screening procedures.
Why it matters
Potential benefit: If successful, this study could enhance the identification of patients who may benefit from cutting-edge cancer treatments.
How similar studies have performed: Other studies involving similar screening and evaluation methods for cancer therapies have shown promise, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: Age \>= 18 years. Patient suspected of having, or with biopsy proven, malignant disease. Patient is able to understand and willing to sign a written informed consent document. Patient is being evaluated for treatment on an NCI-SB protocols. EXCLUSION CRITERIA: Women of child-bearing potential who are pregnant or plan to become pregnant because of the potentially dangerous effects of some of the screening procedures (e.g., nuclear medicine or other imaging scans) on the fetus.
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Steven A Rosenberg, M.D. — National Cancer Institute (NCI)
- Study coordinator: NCI SB Immunotherapy Recruitment Center
- Email: irc@nih.gov
- Phone: (866) 820-4505
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.